New implant could transform diabetes treatment

A new “living, cell‑based” implant created at the Technion – Israel Institute of Technology, in collaboration with MIT, Harvard, Johns Hopkins University and the University of Massachusetts, may provide a self‑regulating treatment for diabetes, according to a peer‑reviewed study published in Science.

How the implant works

The device continuously senses blood‑glucose levels, produces insulin inside the implant, and releases exactly the amount required at the moment it is needed.

In effect, the implant becomes a self‑regulating, drug‑manufacturing organ inside the body, requiring no external pumps, injections or patient intervention.

Overcoming immune rejection

Foreign implants are often rejected by the body’s immune system, a long‑standing obstacle for such therapies.

Researchers addressed this by developing a novel crystalline shield made of engineered therapeutic crystals. The shield prevents immune recognition, enabling the artificial pancreas to function reliably and continuously for several years.

Did You Know? The concept for the self‑regulating implant was first proposed by Assistant Professor Shady Farah in 2018 and has since been refined through collaboration with leading U.S. Institutions.

Expert Insight: The crystalline shield represents a pivotal advance because it tackles the immune‑rejection problem that has stalled many cell‑based therapies. If the shield proves durable in humans, it could open the door to a range of implantable, closed‑loop platforms for chronic diseases beyond diabetes.

Broader implications

While the current focus is on diabetes, the research team envisions adapting the crystalline‑shield technology to treat other chronic conditions that require continuous delivery of biological therapeutics, such as hemophilia and other metabolic or genetic diseases.

The implant has been tested on mice and non‑human primates, a “critical milestone” toward human application, although clinical trials in people have not yet begun.

Frequently Asked Questions

What condition is the new implant designed to treat?

The implant functions as an artificial pancreas, continuously monitoring blood‑glucose levels and delivering insulin to treat diabetes.

How does the implant avoid being rejected by the immune system?

It is encased in a crystalline shield made of engineered therapeutic crystals that hide the implant from immune detection, allowing it to operate for years without rejection.

Has the implant been tested in humans?

Testing has so far been limited to mice and non‑human primates; human trials have not yet started.

What do you think could be the next steps for this technology?